IQVIA Holdings Inc. $IQV Shares Sold by Eastern Bank

Eastern Bank reduced its stake in IQVIA Holdings Inc. (NYSE:IQV) by 93.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 5,646 shares of the medical research company’s stock after selling 78,387 shares during the quarter. Eastern Bank’s holdings in IQVIA were worth $1,091,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Brighton Jones LLC increased its stake in IQVIA by 244.4% in the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock valued at $703,000 after buying an additional 2,537 shares during the period. Empowered Funds LLC lifted its stake in shares of IQVIA by 102.1% in the 1st quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock worth $1,715,000 after acquiring an additional 4,915 shares during the period. Sivia Capital Partners LLC purchased a new stake in shares of IQVIA in the second quarter valued at about $514,000. First Trust Advisors LP increased its stake in shares of IQVIA by 14.8% during the second quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company’s stock worth $14,501,000 after acquiring an additional 11,845 shares during the period. Finally, NewEdge Advisors LLC increased its stake in shares of IQVIA by 5.4% during the second quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company’s stock worth $3,582,000 after acquiring an additional 1,155 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on IQV shares. Mizuho raised their price objective on shares of IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. Evercore reiterated an “outperform” rating and set a $185.00 target price on shares of IQVIA in a research report on Wednesday, April 8th. BMO Capital Markets raised their price target on IQVIA from $210.00 to $270.00 and gave the company an “outperform” rating in a report on Wednesday, July 29th. Deutsche Bank Aktiengesellschaft set a $240.00 price objective on IQVIA in a report on Thursday, July 9th. Finally, Wall Street Zen upgraded IQVIA from a “hold” rating to a “buy” rating in a research report on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $241.88.

Insider Transactions at IQVIA

In related news, insider Bhavik Patel sold 1,855 shares of IQVIA stock in a transaction on Friday, July 31st. The stock was sold at an average price of $235.27, for a total transaction of $436,425.85. Following the completion of the transaction, the insider directly owned 1,348 shares of the company’s stock, valued at approximately $317,143.96. The trade was a 57.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider W Richard Staub sold 5,500 shares of the business’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $232.68, for a total value of $1,279,740.00. Following the sale, the insider owned 13,312 shares in the company, valued at approximately $3,097,436.16. The trade was a 29.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 12,913 shares of company stock valued at $3,098,793. Company insiders own 1.70% of the company’s stock.

IQVIA Trading Down 2.2%

Shares of IQV opened at $228.18 on Wednesday. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. The firm’s 50-day moving average is $197.37 and its two-hundred day moving average is $186.67. IQVIA Holdings Inc. has a twelve month low of $154.50 and a twelve month high of $251.36. The firm has a market capitalization of $37.56 billion, a P/E ratio of 28.31, a PEG ratio of 1.97 and a beta of 1.18.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. The company had revenue of $4.37 billion during the quarter, compared to analysts’ expectations of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The firm’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same period last year, the company posted $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, research analysts predict that IQVIA Holdings Inc. will post 11.61 earnings per share for the current fiscal year.

IQVIA announced that its Board of Directors has approved a share buyback plan on Thursday, May 7th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s management believes its shares are undervalued.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.